Early drug intervention reduces risk of cardiovascular events in rheumatoid arthritis sufferers – U of T Study

July 8, 2019

Share Post

People who develop rheumatoid arthritis (RA) as older adults, benefit from early and sustained use of a drug called Methotrexate (MTX), a treatment considered by many rheumatologists to be a first line of defense in managingHand Of Woman Deformed From Rheumatoid Arthritis the disease. Now, a new study led by Jessica Widdifield, an assistant professor at the Institute of Health Policy Management and Evaluation, has found that patients who have access to MTX earlier in their diagnosis, also reduce their risk of cardiovascular events associated with the disease.

“Rheumatoid arthritis is an inflammatory disease, and patients who develop the condition at an older age have a higher disease activity and inflammation in their joints,” says Widdifield who is also a scientist at Sunnybrook Research Institute and ICES. “This type of chronic systemic inflammation has been linked to atherogenesis, a disease of the arteries, but MTX may also influence this type of inflammation throughout the body, reducing a patient’s cardiovascular risk.”

While MTX as a drug has been vetted for safety and efficacy, it is also a chemotherapeutic agent and an immunosuppressive drug, which means that some family physicians just aren’t comfortable prescribing it. Early access to treatment for rheumatoid arthritis is dependent on a patient’s ability to see a rheumatologist, creating a barrier for older adults that can delay the effectiveness of the drug.

“There are many factors that delay access to treatment, one of which is a shortage of rheumatologists, which leads to longer wait times,” says Widdifield. “Another is that patients might delay presenting to primary care physicians thinking that they are suffering with just arthritis or symptoms of getting older.”

Profile of Jessica Widdifield with green foliage in background
Jessica Widdifield

Widdifield also notes that primary care physicians may not always recognize signs and symptoms of rheumatoid arthritis and the urgency of a referral to a rheumatologist. Further delays in treatment may also result from a rheumatologist opting to use another form of treatment other than MTX.

Each of these barriers can have a negative impact on the ability of MTX to diminish long-term risks including cardiovascular events and even delay helping patients end up remission. According to the study, within the first year of diagnosis, patients who were treated with MTX experienced a lower rate of cardiovascular events, and those that were given the drug continuously and assessed in the last 12 months, reduced their risk by 20%.

Widdifield’s study is the first of its kind to examine the evidence around the effect of timing of MTX initiation in relation to long-term outcomes. With evidence already in place showing that early MTX treatment helped patients end up in remission from the disease, Widdifield felt it was imperative to also assess whether early treatment also reduced cardiovascular risks.

“Our evidence supports the recommendation that rheumatoid arthritis patients should receive methotrexate treatment early and continue to receive it in order to control the disease and reduce their risk of a cardiovascular event,” says Widdifield.

Her study also demonstrates the importance of rheumatologists in providing timely care. In Canada, Widdifield points out that the supply of rheumatologists has not kept up with the needs of our growing and aging population, increasing the burden of symptoms and risks on patients with rheumatoid arthritis.

“We have made great strides in improving care and outcomes for Canadians with rheumatoid arthritis,” says Widdifield, “but future patients may not have the same experience if we don’t also address the impending shortage and maldistribution of rheumatologists across the country.”

Related News

A man in a black suit jacket and light-colored shirt stands in front of a blurred building background. The image has colored bars in the corners: blue and purple in the top left, and orange and green in the bottom right.

IHPME Faculty Presented With Insulin Banting Award for Redefining Diabetes Care

June 20, 2025

Faculty / Research

Read More

IHPME Students Recognized as 2025-26 CGS Doctoral Scholars

June 19, 2025

Research / Students

Read More
A digitally altered photo of three people standing side by side with faces obscured by gray rectangles; the background is a blurred, blue-tinted urban scene with colorful bars in orange, green, and purple in the corners.

IHPME-Affiliated Team Looped Advances in AI Competition

May 27, 2025

Faculty / Research / Students

Read More
A collage of images from the 21st Annual Research and Impact Day. The images include various scenes such as people receiving awards, attendees engaging in discussions, a keynote speaker presenting, and a display table with informational materials.

Bridging Research and Reality: 21st Annual Research and Impact Day Highlights Innovation and Collaboration

May 12, 2025

Faculty / Research / Students

Read More
A group of people are posing for a photo in a classroom. They are standing and kneeling in front of a large white projection screen. The room has wooden paneling on the walls and several desks with chairs arranged in rows. Some individuals are wearing masks, and various casual outfits can be seen.

Innovation in Action: Highlights from the 6th Health Systems AI Hackathon

April 30, 2025

Faculty / Research / Students

Read More
Professional headshot of an individual wearing a maroon blazer and light blue shirt, smiling confidently against a neutral dark grey background. This person has led a study focused on mental health.

IHPME Alumni and Faculty Drive Collaborative Effort to Tackle Inequities in Transgender and Gender Diverse Mental Health Care

March 25, 2025

Faculty / Research / Students

Read More

Sign up for IHPME Connect.

Keep up to date with IHPME’s News & Research, Events & Program, Recognition, e-newsletter.

Subscribe to Connect Newsletter

Get in Contact


Communications

Marielle Boutin
Email Address: ihpme.communications@​utoronto.ca

Manages all IHPME-wide communications and marketing initiatives, including events and announcements.